1. ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А. И. Евдокимова» Минздрава России (Москва, Россия)
2. Северо-Западный государственный медицинский университет им. И. И. Мечникова (Санкт-Петербург, Россия)

Ключевые слова: фиброз,печень,Лаеннек,коллагеновый матрикс,НАСГ

Резюме: Лаеннек - мультикомпонентный препарат на основе гидролизата плаценты, обладающий пролиферативным действием на гепатоциты и фибриннолитическим - на соединительную ткань. В состав препарата входит комплекс ростовых факторов и цитокинов, принимающих участие в процессах нормального функционирования структур печени, что препятствует развитию фиброза. Наше исследование демонстрирует эффективность использования препарата Лаеннек с целью фибринолитического действия в виде монотерапии в течение 4 месяцев у больных НАСГ. Препарат способствовал нормализации показателей крови, цитолитического, холестатического и воспалительного синдромов, улучшению белково-синтетической функции печени, повышению активности ферментного и субстратного звена антиоксидантной защиты, уменьшению активности провоспалительных цитокинов. Подобные изменения снижали выраженность астенического и болевого синдромов, проявления печеночной недостаточности и выраженность фиброза печени.

• Литература всего 68 ⇓ :: .
  1. Gromova O.A. Torshchin I.Yu., Volkov A.Yu., Smarygin S.N., Nazarenko O.A., Karimova I.M. Preparat Laennek: elementnyi sostav i farmakologicheskoe deistvie. Plasticheskaya khirurgiya i kosmetologiya. 2011:2:327-333.
  2. Lazebnik L.B., Radchenko V.G., Golovanova E.V., Zvenigorodskaya L. A. Nealkogol'naya zhirovaya bolezn' pecheni: klinika, diagnostika, lechenie (rekomendatsii dlya terapevtov, 2-versiya). Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2017;138(2):22-37.
  3. Maksimov V.A., Minushkin O.N., Pal'tsev A.I., Saifutdinov R.G., Chernyshev A.L., Gromova R.A., Gusakova E.V., Radchenko V.G., Lazebnik L.B. Rekomendatsii po primeneniyu gidrolizata chelovecheskoi platsenty pri zabolevaniyakh pecheni. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2016;136(12):75-77.
  4. Мinushkin O.N., Dibrova E.A., Karimova I.Ya., et al. «Laennek» – novyi gepatoprotektivnyi preparat dlya lecheniya steatogepatitov razlichnoi etiologii». Kremlevskaya meditsina. 2007;2:65-67.
  5. Minushkin O.N., Leont'ev S.I., Maslovskii L.V., et al. Primenenie diskriminantnoi schetnoi shkaly dlya otsenki fibroobrazovaniya v pecheni u bol'nykh s khronicheskimi gepatitami. Gepatologiya. 2005;1:16-24.
  6. Pavlov Ch.S., Zolotarevskii V.B., Tomkevich M.S. Vozmozhnosti obratimosti tsirroza pecheni. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;1:20-29.
  7. Pavlov Ch.S., Ivashkin V.T. Biopsiya pecheni: metodologiya i praktika segodnya. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(4):65-78.
  8. Pavlov Ch.S., Glushenkov D.V., Ivashkin V.T. Sovremennye vozmozhnosti elastometrii fibro- i akti-testa v diagnostike fibroza pecheni. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2008;4:43-52.
  9. Pavlov Ch.S., Zolotarevskii V.B., Tomkevich M.S. Vozmozhnosti obratimosti tsirroza pecheni. Rossiiskii zhurn al Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;1:20-29.
  10. Radchenko V.G., Seliverstov P.V., Ivanova V.F., Sitkin S.I. Algoritm lecheniya nealkogol'noi zhirovoi bolezni pecheni i rol' mitokhondrial'noi disfunktsii v ee razvitii. Фарматека. 2017;6:12-19.
  11. Radchenko V.G., Seliverstov P.V. Vozrastnye izmeneniya pecheni. Vestnik SZGMU im. I.I. Mechnikova. 2017;9(1):110-116.
  12. Seliverstov P.V., Radchenko V.G. Rol' mitokhondrial'noi tsitopatii pri steatoze u bol'nykh nealkogol'noi zhirovoi bolezn'yu pecheni. Effektivnaya farmakoterapiya. 2017;5:16-24.
  13. Severov M.V. Obratimost' fibroza i tsirroza pecheni pri HCV–infektsii. Gepatologicheskii forum. 2008;1:2-6.
  14. Storozhakov G.I., Ivkova A.N. Patogeneticheskie aspekty fibrogeneza pri khronicheskikh zabolevaniyakh pecheni. Klinicheskie perspektivy gastroenterologii, gepatologii. 2009;2:3-10.
  15. Sherlok Sh., Duli Dzh. Zabolevaniya pecheni i zhelchnykh putei. Prakticheskoe rukovodstvo. Мoscow, GEOTAR-MED, 2002. 864 p.
  16. Albanis E., Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin. Liver Dis. 2001;5:315-334.
  17. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. American Journal of Physiology, Gastrointestinal and Liver Physiology. 2000;279:G245-G249.
  18. Arthur M.J. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002;122:1525-1528.
  19. Asrani S.K., Talwalkar J.A., Kamath P.S., Shah V.H., Saracino G., Jennings L., et al. Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol. 2014;60:934-939.
  20. Bataller R., Brenner D.A. Liver fibrosis. The Journal of Clinical Investigation. 2005;115:209-218.
  21. Bataller R. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal / R. Bataller, K. E. North, D. A. Brenner // Hepatology. - 2003. - No. 37. - Р. 493-503.
  22. Bataller R. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal / R. Bataller, K. E. North, D. A. Brenner // Hepatology. - 2003. - No. 37. - Р. 493-503.
  23. Bataller R. et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells / R. Bataller et al. // Gastroenterology. - 2000. - No. 118. - Р. 1149-1156.
  24. Bataller R. et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver /R. Bataller et al. // Am. J. Physiol. Gastrointest. Liver Physiol. - 2003. - No. 285. - P. G642-G651.
  25. Bataller R. et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis / Bataller R. et al. // J. Clin. Invest. - 2003. - No. 112. - Р. 1383-1394.
  26. Benyon R. C. Is liver fibrosis reversible? / R. C. Benyon, J. P. Iredale // Gut. - 2000. - No. 46. - Р. 443-446.
  27. Brunt E. M. Nonalcoholic steatohepatitis / E. M. Brunt // Semin. Liver Dis. - 2004. - No. 24. - Р. 3-2.
  28. Brun P. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells / P. Brun, I. Castagliuolo, M. Pinzani, G. Palu, D. Martines // Am J Physiol Gastrointest Liver Physiol. - 2005. - Vol. 289, No. 3. - P. G571-G578.
  29. Cadranel J. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF) / J. Cadranel, P. Rufat, F. Degos // Hepatology. - 2000. - No 32. - P. 477-81.
  30. Canbay A. et al. Fas enhances fibrogenesis in the bile ductligated mouse: a link between apoptosis and fibrosis / A. Canbay et al. // Gastroenterology. - 2002. - No. 123. - Р. 1323-1330.
  31. Chen Y., et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism / Y. Chen, S. S. Choi, G. A. Michelotti, I. S. Chan, M. Swiderska-Syn, G. F. Karaca, et al. // Gastroenterology. - 2012. -Vol. 143. - P. 1319-1329.
  32. De Alwis N. M. W. Non-alcoholic fatty liver: the mist gradually clear / N.M.W. De Alwis, C. P. Day // J Hepatol. - 2008. - No. 48. - P. S 105-S 112.
  33. Diego Garcia-Compean. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management / Diego Garcia-Compean, Joel Omar Jaquez-Quintana, Jose Alberto Gonzalez-Gonzalez, Hector Maldonado-Garza// World J Gastroentrol. -2009. - Vol. 15. - No. 3. - P. 280-288.
  34. Gabele E. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell / E. Gabele, D. A. Brenner, R. A. Rippe // Front. Biosci. - 2003. - No. 8. - D 69-D 77.
  35. Gilmore I. et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales / I. Gilmore, A. Burroughs, I. Murray-Lyon, et al. // An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. - 1995. -No. 36. - P. 437-41.
  36. Gressner A. M. Roles of TGF_beta in hepatic fibrosis / A. M. Gressner, R. Weiskirchen, K. Breitkopf, S. Dooley // Front. Biosci. - 2002. -No.7. - P. d793-d807.
  37. Ishak K. et al. Histological grading and staging of chronic hepatitis / K. Ishak, A. Baptista, L. Bianchi, et al. J. Hepatol. - 1995. - No. 2. - P. 696-99.
  38. Iredale J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ / J. P. Iredale // J. Clin. Invest. - 2007. - Vol. 117, No. 3. - P. 539-548.
  39. Issa R. et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix crosslinking / R. Issa et al. // Gastroenterology. - 2004. - No. 126. - Р. 1795-1808.
  40. Kamada Y. et al. Enhanced carbon tetrachloride induced liver fibrosis in mice lacking adiponectin / Y. Kamada et al. // Gastroenterology. -2003. - No. 125. - Р. 1796-1807.
  41. Kanno K., Tazuma S., Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl (4) / K. Kanno, S. Tazuma, K. Chayama // Biochem. Biophys. Res. Commun. - 2003. - No. 308. - Р. 177-183.
  42. Kinnman N. Peribiliary myofibroblasts in biliarytype liver fibrosis / N. Kinnman, C. Housset // Front. Biosci. - 2002. - No. 7. - Р. 496-503.
  43. Knodell R., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis / R. Knodell, K. Ishak, W. Black, et al. // Hepatology. - 1981. - No. 4. -P.431-35.
  44. Lee Y. A., Wallace M. C., Friedman S. L. Pathobiology of liver fibrosis: a translational success story / Y. A. Lee, M. C. Wallace, S. L. Friedman // Gut. - 2015. - No. 64. - P. 830-41. doi: 10.1136/gutjnl-2014-306842.
  45. Macias-Barragan J. Update on the pathophysiology of liver fibrosis. / J. Macias-Barragan // Expert Rev Gastroenterol Hepatol. - 2010. - Vol. 4. - P. 459-472.
  46. Marra F. Chemokines in liver inflammation and fibrosis / F. Marra // Front. Biosci. - 2002. - No. 7. - P. 1899-1914.
  47. Mann D. A. Epigenetics in liver disease / D. A. Mann // Hepatology. - 2014. - Vol. 60. - P. 1418-1425.
  48. Magness S. T. A dual reporter gene transgenic mouse demonstrates heterognity in hepatic fibrogenic cell populations / S. T. Magness, R. Bataller, L. Yang, D. A. Brenner // Hepatology. - 2004. -No. 40. - Р. 1151-1159.
  49. Novo E. Redox mechanisms in hepatic chronic wound healing and fibrogenesis / E. Novo, M. Parola // Fibrogenesis Tissue Repair. - 2008. - P. 1-5.
  50. Novo E., et al. Vascular endothelial growth factor and angiopoietin-1 as hypoxia-dependent autocrine and paracrine factors stimulating migration and chemotaxis of activated human hepatic stellate cells / E. Novo, S. Cannito, E. Zamara, L. Valfre di Bonzo, A. Caligiuri, C. Cravanzola, et al. // Am J Pathol. - 2007. - Vol. 170. - P. 1942-1953.
  51. Oben J. A. et al. Hepatic fibrogenesis requires sympathetic neurotransmitters / J. A. Oben et al. // Gut. - 2004. - No. 53. - Р. 438-445.
  52. Ogawa E. et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with with pegylated interferon alpha-2d and ribavirin / E. Ogawa, N. Furusyo, K. Toyoda, et al. // Antiviral Res. - 2009. - Vol. 83, Issue-2. - P. 127-34.
  53. Olsen A. L., et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation / A. L. Olsen, S. A. Bloomer, E. P. Chan, M. D. Gaca, P. C. Georges, B. Sackey, et al. // Am J Physiol Gastrointest Liver Physiol. - 2011. - Vol. 301. - P. G110-G118.
  54. Parsons C. J. Molecular mechanisms of hepatic fibrogenesis / C. J. Parsons, M. Takashima, R. A. Rippe // J Gastroenterol Hepatol. - 2007. - Vol. 22, No. 1. - P. 79-84.
  55. Pellicoro A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ / A. Pellicoro, P. Ramachandran, J. P. Iredale, J. A. Fallowfield // Nat Rev Immunol. - 2014. - No.14- P. 181-194.
  56. Safadi R. et al. Immune stimulation of hepatic fibrogenesis by CD 8 cells and attenuation by transgenic interleukin_10 from hepatocytes / R. Safadi et al. // Gastroenterology. - 2004. - No. 127. - Р. 870-882.
  57. Sahai A. et al. Upregulation ofosteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model / A. Sahai, P. Malladi, H. Melin_Aldana // Am. J. Physiol.Gastrointest. Liver Physiol. - 2004. - No. 287. - Р. G264-G273.
  58. Sato M. Hepatic stellate cells: unique characteristics in cell biology and phenotype / M. Sato, S. Suzuki, H. Senoo // Cell Struct. Funct. - 2003. - No. 28. - Р. 105-112.
  59. Schwabe R. F. Human hepatic stellate cells express CCR 5 and RANTES to induce proliferation and migration / R. F. Schwabe, R. Bataller, D. A. Brenner // Am. J. Physiol. Gastrointest. Liver Physiol. - 2003. - No. 285. - P. G949-G958.
  60. Schnabl B. Interactions between the intestinal microbiome and liver diseases/ B. Schnabl, D. A. Brenner // Gastroenterology. -2014. - Vol. 146. - P. 1513-1524.
  61. Shek F. W. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? / F. W. Shek, R. C. Benyon // Eur. J. Gastroenterol. Hepatol. - 2004. - No. 16. - Р. 123-126.
  62. Streetz K. L. et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases / K. L. Streetz et al. // Hepatology. - 2003. - No. 38. - Р. 218-229.
  63. Takehara T. et al. Hepatocyte_specific disruption of BclxLleads to continuous hepatocyte apoptosis and liver fibrotic responses / T. Takehara et al. // Gastroenterology. - 2004. - No. 127. - Р. 1189-1197.
  64. Ueberham E. et al. Conditional tetracycline regulated expression of TGF_beta1 in liver of transgenic mice leads to reversible intermediary fibrosis / E. Ueberham et al. // Hepatology. - 2003. - No. 37. - Р. 1067-1078.
  65. Wang H. Effect of acid-sensing ion channel 1a on the process of liver fibrosis under hyperglycemia / H. Wang, Y. H. Wang, F. Yang, X. F. Li // Biochemical and Biophysical Research Communications. - 2015. - Vol. 468. - No. 4. - P. 758-765. www.doi.org/10.1016/j.bbrc.2015.11.029
  66. Yoshida T. et al. SOCS 1 is a suppressor of liver fibrosis and hepatitis_induced carcinogenesis / T. Yoshida et al. // J. Exp. Med. - 2004. - No. 199. - Р.1701-1707.
  67. Yoshiji H. et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenicmouse / H. Yoshiji et al. // Hepatology. - 2002. - No. 36. - Р. 850-860.
  68. Yu C. et al. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride_induced hepatic injury and fibrogenesis / C. Yu et al. // Am. J. Pathol. - 2003. - No. 163. - Р. 1653-1662.

Для цитирования :
Лазебник Л.Б., Радченко В.Г., Селиверстов П.В., Ситкин С.И. и др.СОВРЕМЕННОЕ ПРЕДСТАВЛЕНИЕ О ФИБРОЗЕ ПЕЧЕНИ И ПОДХОДАХ К ЕГО ЛЕЧЕНИЮ У БОЛЬНЫХ НЕАЛКОГОЛЬНЫМ СТЕАТОГЕПАТИТОМ. Экспериментальная и клиническая гастроэнтерология. 2017;148(12):98-108
Загрузить полный текст